![VistaGen Therapeutics, Inc. logo](/logos/VTGN.webp)
VistaGen Therapeutics, Inc.
NASDAQ:VTGN
Overview | Financials
Company Name | VistaGen Therapeutics, Inc. |
Symbol | VTGN |
Currency | USD |
Price | 3.25 |
Market Cap | 87,929,075 |
Dividend Yield | 0% |
52-week-range | 2.45 - 7.1 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Shawn K. Singh J.D. |
Website | https://www.vistagen.com |
An error occurred while fetching data.
About VistaGen Therapeutics, Inc.
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD